Explore more publications!

Nestle Announces Expansion of Baby Formula Recall in France

(MENAFN) The Swiss food giant Nestle revealed Tuesday it is pulling an additional batch of Guigoz-branded infant formula from shelves following France's decision to impose stricter limits on a dangerous toxin.

In a written statement, Nestle France declared: "Our quality standard is based on the strictest cereulide detection threshold in the industry: we aim for the total absence of detectable cereulide in our infant milks." The company continued: "This requirement, which guides all our decisions, leads us today to proceed with the additional recall of a single batch of Guigoz Optipro Relais 1 (0–6 months)."

The expanded recall targets only one specific batch of the formula designed for infants aged 0-6 months. Nestle emphasized that no other Guigoz products face removal and maintained that remaining products are safe for consumption.

Cereulide—a toxin capable of causing nausea, vomiting, and diarrhea—has triggered multiple Nestle baby food product withdrawals in recent weeks. The contamination concerns have prompted heightened scrutiny of infant nutrition safety standards across the industry.

The announcement comes as regulatory pressure intensifies on manufacturers to eliminate even trace amounts of the harmful substance from products intended for vulnerable infants.

MENAFN05022026000045017169ID1110699090


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions